INTRODUCTION
With the development of the third-generation gene scissors, CRISPR-Cas9, new Gene-Editing technologies and clinical medicines are rapidly developing in Korea. For example, researchers recently conducted a genetically modified cell therapy study in Korea, which differentiated pluripotent stem cells of hemophilia patients into hepatocytes by reprogramming the hemophiliac somatic cells and transplanting these hepatocytes into the patient's liver (Ministry, 2015) . Following the enactment of Article 14 of the Framework Act on Science and Technology in 2015, the Ministry of Science, ICT and Future Planning conducted a 'Technology Impact Assessment' to evaluate the impact of new development in science and technology on the economy, society, culture, ethics, and environment. The assessment revealed that by 2019, the market for genetic editing is expected to reach $1.6 billion (Ministry, 2015) , and research is underway to apply genetic scissors to treat diseases such as AIDS and anemia in various countries around the world.
In this situation it is very important to clarify how Korean laws regulate gene editing or how the present legislation is to be interpreted regarding gene editing.
THE REGULATION OF KOREAN BIOACT (I): CASE OF (BORN) HUMANS
The most important law in Korea that contains regula-tions for gene editing is the Bioethics and Biosafety Act (hereinafter "BioAct"). The BioAct does not specify and regulate 'gene editing' itself. However, assuming that genetic editing is used in the process of research and treatment, we look to the specific details of the regulations for research on humans as well as gene therapy research in order to see how genetic editing is regulated under the BioAct.
Regulation for research on gene therapy
Article 47 of the current BioAct provides for the regulations of gene therapy under the title "Gene Therapy". The last revision of this article was on December 29, 2015.
Until the last revision the contents have been changed and this revision process is highly suggestive in interpreting Even if we interpret-as the legislator mentioned-the 'possibility of genetic alteration' as 'heritability to the next generation' and interpret the type of procedure in § 47(2) as a 'simple' transmission of a genetic material or a cell into which a genetic material has been introduced, it is not always obvious that gene editing is an act corresponding to type (1).
THE REGULATION OF KOREAN BIOACT (II): CASE OF EMBRYOS, OOCYTES, SPERM, AND FETUSES

A total ban on treatment
BioAct 2016 provides that "no gene therapy [is] to be applied to an embryo, ovum, sperm,or fetus" (referred to as One possible interpretation is that 'research on gene therapy' includes 'research on the gene therapy of a born human using embryos', considering that § § 47 (1) and (2) of BioAct 2016, unlike § 47(3), stipulate 'research on gene therapy' rather than 'gene therapy'. It is interpreted that although § § 47(1) and (2) use the term 'human body', it is possible to conduct gene therapy research for human beings using embryos. Of course, the following arguments can be raised against this interpretation: Articles § § 47 (1) and (2) of BioAct 2016 explicitly use the term 'human body' and this provision-as mentioned before-is a comprehensive regulation of gene therapy, even if it specifies research on gene therapy.
Another possible interpretation is to emphasize that § § 47(1) and (2) of BioAct 2016 do not clearly stipulate 'research on gene therapy using embryos' in the same context as the above counter-argument. On this basis, some interpret this to mean that research using embryos could be subject to the provisions on residual embryo studies ( § 29) and to the study of somatic-cell cloning and parthenogenic embryos ( § 31) (Jun, 2015; Kim et al., 2015a limits the study range of the remaining embryos to: "1.
Research for the development of therapies for infertility and technology for contraception", "2. Research on therapies for muscular dystrophy or other rare or incurable diseases specified by Presidential Decree", and "3. Research for other purposes specified by Presidential Decree through deliberation by the National Committee". Furthermore,
Article 12 of the Enforcement Decree of the Bio Act (2016) specifically addresses the range of diseases for which research can be conducted in § 29 (1)(1)- (3) of BioAct 2016.
Therefore, some have criticized that the scope of the residual embryo research is very narrow to apply to research on gene therapy (Park and Ryoo, 2016) . In other words, it seems unlikely that gene therapy research using embryos can be included within the research of specific disease treatments specified in § 29(1) of BioAct 2016.
THE REGULATION OF PHARMACEUTI-CALS AFFAIRS ACT, ETC.
Due to the fact that gene therapy products are regarded as drugs, they fall under different regulations. For instance, Products" with a notice, and regulates the criteria for product approval. In particular, the notification regulates the criteria for licensing items for gene therapy products.
Problems with approval of gene therapy products
Article 31 In that case, it seems that in § 3(2) of the Notification Act it is not logically contradictory to maintain the or-condition (contrasting with the Health and Welfare Committee of the Korean National Assembly review report). 
Problems with clinical trials
